Chinese herbal treatment shows signs of effectiveness in bone marrow recovery – sciencedaily


UCLA researchers found that a Chinese herbal diet called TSY-1 (Tianshengyuan-1) increased telomerase activity in normal blood cells but decreased it in cancer cells. Telomerase is an enzyme responsible for the production of telomeres, which play an important role in the regulation of normal cell division. These results indicate that telomerase-based treatments may play an important role in the treatment of both blood cell deficiency and cancer.

Over 80% of cancers have increased telomerase activity, and other medical conditions are also associated with reduced or abnormal telomerase function. The ability to increase or decrease telomerase activity has important implications for the treatment of cancers in which an insufficient number of blood cells are produced. When a person’s bone marrow is unable to meet the need for healthy blood cells, bone marrow failure is triggered. Bone marrow failure affects about seven in 100,000 people each year.

TSY-1 has been used in China for many years to treat aplastic anemia, a disease in which the body stops making enough new blood cells and myelodysplastic syndrome or preleukemia; both are associated with a telomerase abnormality.

The five-year study, led by Dr. Jianyu Rao, member of the Comprehensive Cancer Center at UCLA Jonsson, measured the ability of TSY-1 to affect telomerase activity in cancer cell lines, including one known under the name HL-60, as well as in normal mononuclear peripheral blood. and hematopoietic stem cells. Rao’s team used a variety of approaches, including testing for telomerase activity, measuring cell growth, and profiling gene expression in cells treated with TSY-1, to determine how it works. The results showed that the target of TSY-1 activity is the TERT gene. TERT is the main regulatory component of telomerase activity.

The results provide the basis and support for further clinical studies aimed at demonstrating the clinical benefits of this treatment for cancer and blood cell deficiencies.

The study is published online in the journal OncoTarget.

Source of the story:

Materials provided by University of California, Los Angeles (UCLA), Health Sciences. Original written by Reggie Kumar. Note: Content can be changed for style and length.

Source link


Leave A Reply